Reflux Esophagitis

Reflux esophagitis is an inflammatory condition of the esophageal mucosa caused by the retrograde flow of gastric contents, including hydrochloric acid, pepsin, and bile salts, into the esophagus. This condition results in mucosal injury, inflammation, and potentially ulceration, leading to clinical signs such as regurgitation, dysphagia, and excessive salivation. In veterinary medicine, reflux esophagitis is commonly associated with anesthesia, hiatal hernia, or chronic vomiting. The severity can range from mild, self-limiting inflammation to severe ulceration with stricture formation. The disease is classified based on endoscopic findings, including the presence of erythema, erosions, ulcerations, and strictures. Systemic complications may include aspiration pneumonia and malnutrition due to decreased food intake.

The primary cause of reflux esophagitis is the abnormal relaxation of the lower esophageal sphincter (LES) or increased intra-abdominal pressure, allowing gastric contents to enter the esophagus. Specific etiologies include: 1) Anesthesia-related: Administration of drugs that decrease LES tone (e.g., anticholinergics, alpha-2 agonists) or increase intra-gastric pressure (e.g., opioids) during general anesthesia, especially in brachycephalic breeds. 2) Hiatal hernia: Congenital or acquired displacement of the gastroesophageal junction into the thoracic cavity, leading to reflux. 3) Chronic vomiting: Repeated vomiting exposes the esophagus to gastric acid and pepsin. 4) Gastric outflow obstruction: Pyloric stenosis or foreign bodies increase gastric pressure. 5) Iatrogenic: Indwelling nasogastric tubes or esophageal foreign bodies can cause mechanical irritation and reflux. 6) Neuromuscular disorders: Conditions affecting esophageal motility, such as megaesophagus, can predispose to reflux. 7) Dietary factors: High-fat diets may decrease LES pressure. 8) Drugs: Certain medications like theophylline, diazepam, and calcium channel blockers can reduce LES tone. 9) Infectious agents: Secondary bacterial or fungal infections (e.g., Candida) can complicate reflux esophagitis, especially in immunocompromised patients.

Reflux esophagitis is most commonly diagnosed in dogs, with a higher prevalence in brachycephalic breeds such as Bulldogs, Pugs, and Boston Terriers due to anatomical abnormalities like hiatal hernia. Cats are also affected, but less frequently. There is no clear sex predilection. The condition can occur at any age, but anesthesia-related reflux is more common in middle-aged to older animals undergoing surgical procedures. Breed-specific genetic predispositions include a higher incidence of hiatal hernia in English Bulldogs and Shar-Peis. Environmental factors such as obesity and high-fat diets may increase the risk. The incidence of anesthesia-related reflux esophagitis is estimated to be around 10-15% in dogs undergoing general anesthesia, though clinical signs may be subclinical in many cases.

The pathophysiology of reflux esophagitis involves a complex interplay of mucosal defense mechanisms and aggressive factors. The esophageal mucosa is normally protected by the LES, which maintains a pressure gradient between the stomach and esophagus, and by esophageal peristalsis that clears refluxed material. When these defenses are compromised, gastric acid and pepsin cause direct mucosal injury. Acid diffuses into the mucosal cells, leading to cellular acidification and necrosis. Pepsin, activated by acid, digests the extracellular matrix and exacerbates tissue damage. Bile salts and pancreatic enzymes, present in duodenogastric reflux, further damage the mucosal barrier. The inflammatory response involves the release of pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-alpha) and recruitment of neutrophils and eosinophils, leading to mucosal edema, erythema, and ulceration. Chronic inflammation can stimulate fibrosis and stricture formation. Additionally, reflux can trigger vagally mediated reflexes, causing bronchospasm and aspiration pneumonia. The severity of injury depends on the frequency, duration, and composition of refluxate, as well as the integrity of mucosal defenses.

Predisposing factors for reflux esophagitis include: 1) Anatomical abnormalities: Hiatal hernia, gastroesophageal intussusception, and brachycephalic airway syndrome. 2) Anesthesia-related: Use of drugs that reduce LES tone (e.g., atropine, glycopyrrolate, acepromazine, xylazine) and prolonged recumbency. 3) Obesity: Increased intra-abdominal pressure. 4) Dietary factors: High-fat diets, overfeeding, and feeding immediately before anesthesia. 5) Concurrent diseases: Gastric dilatation-volvulus, pyloric stenosis, chronic kidney disease (causing uremic gastritis), and hyperacidity syndromes. 6) Medications: Corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and anticholinergics. 7) Neuromuscular disorders: Megaesophagus, myasthenia gravis, and esophageal dysmotility. 8) Stress: Critical illness or trauma may increase gastric acid secretion. 9) Age: Older animals may have decreased LES tone. 10) Genetic predisposition: Certain breeds, such as English Bulldogs, are more prone to hiatal hernia.

Clinical signs of reflux esophagitis vary depending on the severity and duration. In peracute cases (e.g., post-anesthesia), signs may appear within 24-48 hours and include: 1) Regurgitation of undigested food or saliva, often shortly after eating. 2) Excessive salivation (ptyalism). 3) Dysphagia (difficulty swallowing). 4) Pain on swallowing (odynophagia), evidenced by crying or pawing at the mouth. 5) Decreased appetite or anorexia. 6) Weight loss in chronic cases. 7) Coughing or gagging, especially if aspiration pneumonia develops. 8) Fever if secondary infection occurs. In chronic cases, signs may be more subtle, with intermittent regurgitation and reluctance to eat. Physical examination may reveal signs of dehydration, poor body condition, and oral ulcerations if severe. Auscultation of the lungs may reveal crackles if aspiration pneumonia is present. In severe cases, esophageal stricture can cause complete obstruction, leading to acute regurgitation and hypersalivation.

Differential diagnoses for reflux esophagitis include: 1) Esophageal foreign body: History of ingestion, acute onset, and radiographic evidence of a radiopaque object. 2) Esophageal stricture: Often a sequela of reflux, but can be primary; barium swallow shows narrowing. 3) Megaesophagus: Generalized esophageal dilation on radiographs, often with regurgitation; may be congenital or acquired. 4) Esophageal neoplasia (e.g., squamous cell carcinoma): Older animals, weight loss, and mass lesion on imaging. 5) Esophagitis due to caustic ingestion: History of exposure to irritants. 6) Hiatal hernia: May be asymptomatic or cause reflux; diagnosed via radiography or endoscopy. 7) Gastric dilatation-volvulus: Acute, severe abdominal distension and shock. 8) Chronic vomiting from other causes (e.g., pancreatitis, renal disease): Differentiated by laboratory findings and imaging. 9) Myasthenia gravis: Generalized weakness, megaesophagus, and positive acetylcholine receptor antibody titer. 10) Oral cavity disease (e.g., dental disease, stomatitis): Oral examination reveals lesions. Definitive diagnosis of reflux esophagitis is based on endoscopy, which shows characteristic mucosal changes.

The diagnostic approach to reflux esophagitis should be systematic: 1) History and physical examination: Identify risk factors (e.g., recent anesthesia, breed) and clinical signs. 2) Baseline laboratory tests: Complete blood count (CBC), serum biochemistry, and urinalysis to rule out systemic diseases. 3) Thoracic radiographs: Evaluate for megaesophagus, hiatal hernia, aspiration pneumonia, or esophageal foreign body. 4) Esophagoscopy (gold standard): Direct visualization of the esophageal mucosa to assess erythema, erosions, ulcerations, and strictures. Biopsies may be taken for histopathology. 5) Barium swallow (fluoroscopy): If endoscopy is not available, to assess esophageal motility and identify strictures or hiatal hernia. 6) Esophageal manometry: May be used in referral settings to measure LES pressure and motility. 7) pH monitoring: 24-hour esophageal pH monitoring is rarely used in veterinary medicine but can confirm acid reflux. 8) Response to therapy: A therapeutic trial with acid suppressants and prokinetics may support the diagnosis. The algorithm should prioritize endoscopy for definitive diagnosis and to rule out other causes.

Laboratory findings in reflux esophagitis are often nonspecific. Hematology may show mild neutrophilia or stress leukogram if inflammation or infection is present. Serum biochemistry may reveal dehydration (elevated total protein, BUN, creatinine) and electrolyte imbalances (hypokalemia, hypochloremia) due to vomiting or regurgitation. In cases with aspiration pneumonia, CBC may show leukocytosis with a left shift. Blood gas analysis may indicate metabolic alkalosis if vomiting is severe. Specific biomarkers are not established for reflux esophagitis, but C-reactive protein (CRP) may be elevated in inflammatory conditions. Serology and PCR are not typically indicated unless infectious causes are suspected. Urinalysis is usually unremarkable. In chronic cases, hypoalbuminemia may occur due to malnutrition. Overall, laboratory tests are primarily used to rule out other diseases and assess complications.

Imaging plays a crucial role in the diagnosis of reflux esophagitis and its complications. Thoracic radiographs may show: 1) Esophageal dilation (megaesophagus) if concurrent. 2) A soft tissue opacity in the caudal thorax suggestive of hiatal hernia. 3) Alveolar pattern in the lung fields if aspiration pneumonia is present. 4) Gas-filled esophagus in some cases. Barium swallow (fluoroscopy) is useful to evaluate esophageal motility and identify strictures, which appear as focal narrowing with proximal dilation. Ultrasonography is not typically used for esophageal evaluation but may be helpful to assess the gastroesophageal junction and rule out gastric outflow obstruction. Computed tomography (CT) can provide detailed anatomy of the esophagus and surrounding structures, especially in cases of suspected neoplasia or hiatal hernia. Magnetic resonance imaging (MRI) is rarely indicated. Endoscopy is the most sensitive imaging modality, allowing direct visualization of mucosal erythema, erosions, ulcerations, and strictures. It also enables biopsy collection. Fluoroscopy can also be used to assess gastroesophageal reflux during swallowing.

Cytology and histopathology are essential for confirming the diagnosis and assessing the severity of reflux esophagitis. Endoscopic brush cytology may reveal inflammatory cells (neutrophils, eosinophils) and reactive epithelial changes. Histopathological examination of esophageal biopsies typically shows: 1) Epithelial hyperplasia or erosion/ulceration. 2) Inflammatory infiltrate, predominantly neutrophils and lymphocytes, with eosinophils in some cases. 3) Fibrosis in chronic cases. 4) Ballooning degeneration of epithelial cells. 5) Presence of bile pigments if bile reflux is significant. Special stains (e.g., Gram stain, PAS) may be used to identify infectious agents. The severity of histologic changes correlates with endoscopic findings. In cases of stricture, biopsy may show dense fibrous tissue. Histopathology is also important to rule out neoplasia.

Treatment of reflux esophagitis aims to reduce gastric acidity, promote esophageal healing, and manage complications. The therapeutic approach includes: 1) Dietary management: Feed small, frequent meals of a low-fat, low-protein diet to minimize gastric volume and pressure. Avoid feeding immediately before anesthesia. 2) Acid suppression: Proton pump inhibitors (PPIs) are the mainstay, e.g., omeprazole at 0.5-1 mg/kg PO q12h or q24h. In severe cases, may be given IV. Histamine-2 receptor antagonists (e.g., famotidine at 0.5-1 mg/kg PO/IV q12h) can be used as an alternative. 3) Prokinetic agents: To increase LES tone and promote gastric emptying, e.g., metoclopramide at 0.2-0.4 mg/kg PO/SC q8h, or cisapride (where available) at 0.5 mg/kg PO q8h. 4) Mucosal protectants: Sucralfate at 0.5-1 g per dog or 250-500 mg per cat PO q8h, given as a slurry, to coat the esophageal mucosa. 5) Analgesia: If odynophagia is severe, consider opioids (e.g., buprenorphine at 0.01-0.02 mg/kg IV/IM q8-12h) or other pain management. 6) Treatment of complications: If aspiration pneumonia develops, antibiotics (e.g., amoxicillin-clavulanate at 12.5-25 mg/kg PO q12h) and supportive care are indicated. 7) Surgical intervention: For hiatal hernia or severe stricture, surgical correction (e.g., fundoplication) or balloon dilation of strictures may be necessary. 8) Supportive care: Fluid therapy for dehydration, antiemetics (e.g., maropitant at 1 mg/kg SC q24h) if vomiting is present. 9) Management of underlying causes: Treat any concurrent diseases (e.g., renal disease, hyperacidity).

The prognosis for reflux esophagitis is generally good if diagnosed early and treated appropriately. Mild cases may resolve within 1-2 weeks with medical therapy. Moderate to severe cases may take several weeks to heal. The presence of esophageal stricture carries a guarded prognosis, as strictures may require repeated balloon dilation and can recur. Mortality is low unless complications such as aspiration pneumonia or severe malnutrition occur. Negative prognostic indicators include: 1) Development of stricture. 2) Aspiration pneumonia. 3) Underlying diseases such as megaesophagus or neoplasia. 4) Poor response to medical therapy within 2 weeks. 5) Chronic weight loss. With appropriate management, most animals regain normal esophageal function, but long-term acid suppression may be required in some cases.

Follow-up care for reflux esophagitis includes: 1) Recheck examination within 1-2 weeks after initiation of therapy to assess clinical response. 2) Serial monitoring of body weight and nutritional status. 3) Repeat endoscopy after 2-4 weeks to evaluate mucosal healing, especially in severe cases. 4) If stricture is present, repeat balloon dilation may be needed, with follow-up endoscopy every 1-2 weeks until stable. 5) Long-term management may involve continued acid suppression (e.g., omeprazole) at the lowest effective dose, and dietary modifications. 6) Monitor for signs of aspiration pneumonia (cough, fever, dyspnea) and treat promptly. 7) If an underlying cause (e.g., hiatal hernia) is identified, surgical correction may be recommended, with postoperative follow-up. 8) Adjust medications based on response and potential side effects. 9) Educate owners on feeding practices (elevated feeding, small meals) to reduce reflux risk.

Pearls: 1) Always consider reflux esophagitis in any dog or cat that regurgitates after anesthesia. 2) Use proton pump inhibitors as first-line therapy, as they are more effective than H2 blockers. 3) Administer sucralfate as a slurry on an empty stomach to maximize mucosal coating. 4) In brachycephalic breeds, evaluate for hiatal hernia if reflux is recurrent. 5) Early endoscopic evaluation is key to prevent stricture formation. Pitfalls: 1) Do not use metoclopramide as a sole treatment; it is less effective than PPIs. 2) Avoid feeding immediately after anesthesia; wait at least 12 hours. 3) Do not use corticosteroids for reflux esophagitis, as they may delay healing. 4) Do not overlook concurrent aspiration pneumonia; treat aggressively. 5) Do not assume that clinical improvement means complete healing; repeat endoscopy may be needed. 6) Avoid using anticholinergics in anesthetized patients at risk for reflux.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for reflux esophagitis: 1) Omeprazole: Dogs: 0.5-1 mg/kg PO q12h or 1 mg/kg PO q24h; Cats: 0.5-1 mg/kg PO q12h. For severe cases, may be given IV at 0.5-1 mg/kg q24h. Duration: 2-4 weeks or longer if needed. Adjust in hepatic impairment. 2) Famotidine: Dogs: 0.5-1 mg/kg PO/IV q12h; Cats: 0.5-1 mg/kg PO/IV q12h. Less potent than PPIs. 3) Metoclopramide: Dogs: 0.2-0.4 mg/kg PO/SC q8h; Cats: 0.2-0.4 mg/kg PO/SC q8h. Use with caution in renal impairment. 4) Cisapride: Dogs: 0.5 mg/kg PO q8h; Cats: 0.5 mg/kg PO q8h. Not available in all countries. 5) Sucralfate: Dogs: 0.5-1 g PO q8h; Cats: 250-500 mg PO q8h. Administer as slurry on empty stomach. 6) Buprenorphine: Dogs: 0.01-0.02 mg/kg IV/IM q8-12h; Cats: 0.01-0.02 mg/kg IV/IM q8-12h. For pain control. 7) Amoxicillin-clavulanate: Dogs: 12.5-25 mg/kg PO q12h; Cats: 12.5-25 mg/kg PO q12h. For aspiration pneumonia. 8) Maropitant: Dogs: 1 mg/kg SC q24h; Cats: 1 mg/kg SC q24h. For vomiting. Contraindications: PPIs may cause hypergastrinemia with long-term use; monitor. Metoclopramide may cause neurologic signs at high doses. Sucralfate may interfere with absorption of other drugs; separate by 2 hours.

Evidence-based literature on reflux esophagitis in veterinary medicine is limited but includes: 1) A study by Zacuto et al. (2012) evaluated the efficacy of omeprazole versus famotidine in dogs with experimentally induced reflux esophagitis, showing superior healing with omeprazole. 2) A consensus statement from the ACVIM on gastrointestinal diseases (2019) recommends PPIs as first-line therapy for esophagitis. 3) Research by Pratschke et al. (2014) highlighted the association between brachycephalic breeds and hiatal hernia, emphasizing the need for surgical correction in refractory cases. 4) A retrospective study by Gualtieri et al. (2006) reported that esophageal stricture formation is a common complication of severe reflux esophagitis, and early intervention with balloon dilation improves outcomes. 5) A study by Lecoindre et al. (2015) evaluated the use of cisapride in cats with reflux esophagitis, showing improved LES pressure. 6) Guidelines from the European College of Veterinary Internal Medicine (ECVIM) recommend a combination of acid suppression and prokinetics for management. Overall, the evidence supports the use of PPIs and prokinetics, with surgical intervention for anatomical abnormalities.